# OnCo record mpn-driver-mutations (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/mpn-driver-mutations/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "mpn-driver-mutations" ;
  schema:name "MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden"@en ;
  schema:alternateName "JAK2 V617F"@en, "JAK2 mutation"@en, "JAK2-positive"@en, "JAK2-negative"@en, "JAK2 exon 12"@en, "CALR"@en, "CALR mutation"@en, "CALR type 1"@en, "CALR type 2"@en, "MPL W515"@en, "MPL mutation"@en, "triple-negative MPN"@en, "triple negative myeloproliferative neoplasm"@en, "JAK2 allele burden"@en, "JAK2 variant allele fraction"@en, "MPN driver mutation"@en ;
  schema:description "Almost every polycythaemia vera and most essential thrombocythaemia and myelofibrosis carry one of three mutations (JAK2 V617F, CALR or MPL) that jam the growth signal on; finding one confirms the diagnosis is a true blood cancer rather than a reaction to something else, and the mutation type and how much of the blood carries it shape the risk of clots and progression."@en ;
  schema:url <https://onco.cc/terms/mpn-driver-mutations/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/targets/jak2/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/vaf/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/interferon-alfa/>, <https://onco.cc/drugs/hydroxyurea/>, <https://onco.cc/terms/ipset-thrombosis/>, <https://onco.cc/terms/dipss-mipss70/>, <https://onco.cc/terms/molecular-response/> ;
  onco:cancers <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/essential-thrombocythaemia/>, <https://onco.cc/cancers/primary-myelofibrosis/> .